Table 3.
Covariate | Hazard Ratio | 95% CI | P |
---|---|---|---|
Treatment arm | |||
R-BEAM | 1.00 | .66 | |
B-BEAM | 1.08 | 0.76 to 1.54 | |
Disease status at transplantation | |||
CR | 1.00 | .008 | |
Not in CR | 1.63 | 1.14 to 2.33 |
Abbreviations: B-BEAM, iodine-131 tositumomab plus carmustine, etoposide, cytarabine, and melphalan; CR, complete remission; PFS, progression-free survival; R-BEAM, rituximab plus carmustine, etoposide, cytarabine, and melphalan.